周一，H.C. Wainwright分析师Andrew Fein将Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX )的目标价从之前的535美元上调至550美元，同时维持对该股的买入评级。根据 InvestingPro ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $470.37, marking a +1.88% move from the previous day.

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price lifted by HC Wainwright from $535.00 to $550.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) gapped up prior to trading on Friday after Scotiabank raised their price target on the stock from $430.00 to $433.00. The stock had ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) on January 31 and set a price ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

周五，BMO Capital Markets上调了Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX )的股票目标价，从520美元提高到545美元，同时维持"优于大市"评级。根据 InvestingPro 数据，该股目前交易价为452.73美元，低于分析师330美元至591美元的目标区间。此次调整是在Suzetrigine（现品牌名为Journavx ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...